The deal with NBE includes a $25 million upfront payment ... a license to an ADC developed by Iconic Therapeutics – called ICON-2 – which targets the tissue factor (TF) pathway thought to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback